SPOT X Y PI MW AC MAPPING METHODS PMF MS PEPTIDES AMINO ACID OD VOLUME PATHOLOGICAL LEVEL EXPRESSION *POSITIONAL VARIANTS COMMENT: SUBUNIT COMMENT: MISCELLANEOUS 89 48 85 4.86 33,544 P02760 111 46 103 4.96 32,167 P02760 112 71 104 5.07 31,046 P02760 Im 769.468 (1.09); 824.448 (2.67); 1235.708 (3.17); 1312.129 (1.2); 2325.211 (5.14); TRYPSIN {private} [1] 769.468 (1.09); 524.448 (2.67); 435.708 (3.17); 512.129 (1.2) 408 104 346 5.12 23,908 P02760 Co (S)RLDMoxDSIIAEVK(K),352-363; (S)SSLEAAIADAEQR(E),428-440 {private} 408 104 346 5.12 23,908 P02741 408 104 346 5.12 23,908 P13693 [1001.5:2] 669.468 (4.09); 324.448 (2.67); 435.708 (3.17); 512.129 (1.2) (R)SLDMoxDSIIAEVK(A),252-263 B=12, Z=13.7, S=3.7, H=0.3, G=11.8, T=5.2, A=11.3, P=3.5, Y=2.5 {private} 0.999 0.888 Increased During the Acute-Phase Reaction; Decreased During Emphysema Homodimer (By similarity) Possible Signal 408 104 346 5.12 23,908 P13693 [1200.7:1] 869.468 (3.09); 524.448 (2.67); 635.708 (3.17); 712.129 (1.2) (S)RLDMoxDSIIAEVA(E),222-233 B=12, Z=13.7, S=3.7, H=0.3, G=11.8, T=5.2, A=11.3, P=3.5, Y=2.5 {private} 0.999 0.888 Increased During the Acute-Phase Reaction; Decreased During Emphysema High expression in strain Homodimer (By similarity) 408 104 346 5.12 23,908 P13693 [1500:2]969.468(3.09),724.448(2.67),435.708(3.17) + [1700:1]1169.468(3.09),1024.448(2.67),35.708(3.17),412.129(1.2) 397 362 331 4.43 32,375 Q99TY2 *Low expression in strain Some rare variants Single Chain 397 362 331 4.43 32,375 P11111 397 362 331 4.43 32,375 P12345 PMF,MS/MS 1473.868 (7.11); 1491.913 (0.99); 2225.211 (5.14); TRYPSIN (S)SSLEAAIADAEQR(E),428-440 465 382 385 4.88 27,200 Q99TY2 No expression in strain 900 300 205 4.99 30,375 PMF,MS/MS 1413.868 (7.23); 1291.913 (3.99); 2221.211 (4.14); TRYPSIN (S)SSLEAAIASSLLEQR(E),326-340 901 113 24 5.99 49,999 PMF,MS/MS 1513.868 (7.23); 1391.913 (3.99); 2321.211 (4.14); TRYPSIN (S)AALEAAIASSLLEQR(E),336-350